SJL2-1

SJL2-1 is a PRMT5 inhibitor, with an IC50 of 1.56 μM. SJL2-1 suppresses proliferation, migration, and invasion in prostate cancer cells. SJL2-1 promotes apoptosis and blocks the cell cycle at the G0/G1 phase. SJL2-1 can target the binding of PRMT5 in cells and inhibit the methylation and expression of the androgen receptor. SJL2-1 can be used for the study of early androgen-sensitive prostate cancer and advanced castration-resistant prostate cancer (CRPC) [1].

Product Specifications

UNSPSC

12352005

Target

11β-HSD; Androgen Receptor; Histone Methyltransferase

Related Pathways

Epigenetics; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

CC1=CN(CC(CN2C(C)C(C=CC=C3)=C3CC2)O)C4=CC=CC=C41

Molecular Formula

C22H26N2O

Molecular Weight

334.45

References & Citations

[1]Diao T, et al. Identification of a Selective Cell-Active Inhibitor of Protein Arginine Methyltransferase 5 (PRMT5) for the Treatment of Prostate Cancer by Structure-Based Virtual Screening. Chem Biol Drug Des. 2025 Jun;105 (6) :e70136.